Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine – A retrospective single center experienceMichael Leisch, Lisa Pleyer, Nadja Lindlbauer et al.|Leukemia Research|2017Cited by 20
Austrian Real-world Experience With Standard of Care Brexucabtagene Autoleucel in Patients With Relapsed or Refractory Mantle-Cell LymphomaStefan Koeck, Thomas Melchardt, Natalia Rotter et al.|Transplantation and Cellular Therapy|2026Cited by 1
Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T NetworkJakob Rudzki, Philipp Wohlfarth, Nina Worel et al.|Blood|2022Cited by 1
Author response for "Historic real-world outcomes and future benchmarks for patients with diffuse large B-cell lymphoma receiving first- and second-line therapy in Austria – a large single-center experience"Michael Leisch, Thomas Melchardt, Dominik Kiem et al.|Unknown|2025Cited by 0
Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple MyelomaIrene Straßl, Maria‐Theresa Krauth, Alexander Nikoloudis et al.|Transplantation and Cellular Therapy|2026Cited by 0